Taken together, these results show that BRCA2 mutations can be detected in a substantial proportion of high-risk prostate cancer patients and that the presence of a BRCA2 mutation is associated with a poor response to docetaxel in the majority, but not all patients. This evidence concerns the gene BRCA2 and prostate carcinoma.